In addition to enzyme prodrug therapy, MSCs transduced with anticancer protein ligands, such as TRAIL, TNF-α, and NK-4, and immunomodulatory cytokines, such as IL-2 and IL-12, increase the survival rates of tumor-bearing rodents [223]. This evidence concerns the gene IL2 and neoplasm.